Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture
Anticancer Research · 2023
DOI: 10.21873/anticanres.16239 ↗Kurz gefasst
Fallbericht in der Zeitschrift Anticancer Research, 2023. Verfasst von Tatsunori Miyata und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan; tatsunori_miyata@yahoo.co.jp. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Peritoneal Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: Conversion surgery (CS) following atezolizumab plus bevacizumab (Atez+Bev) is a treatment strategy for unresectable hepatocellular carcinoma (UR-HCC). Herein, we report a case of CS after transcatheter arterial embolization (TAE) and Atez+Bev for primary HCC with peritoneal metastases and multiple liver metastasis after HCC rupture. CASE REPORT: A 75-year-old man with a suspected ruptured HCC in segment 4b was referred to the National Hospital Organization Kumamoto Medical Center. TAE was performed to stop the bleeding. Subsequently, 15 courses of Atez+Bev were administered for UR-HCC with primary tumor, peritoneal metastasis, and multiple liver metastases. Multiple liver metastases and peritoneal metastasis resolved 7 months after initiation of Atez+Bev. The primary HCC had shrunk, but the patient decided not to continue treatment because of severe numbness in his fingers. Six months after stopping Atez+Bev, CS was performed because no new lesions were observed, and the patient wished to become cancer-free by resection of the remaining tumor. HCC was successfully resected, and he was discharged without any complications. The pathological findings demonstrated that there was no remnant viable HCC. CONCLUSION: We herein present a case of CS following TAE and Atez+Bev for unresectable and ruptured HCC. The patient did not require chemotherapy after CS and is alive and recurrence-free for 7 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan; tatsunori_miyata@yahoo.co.jp.
- Department of Gastroenterological Surgery, Kumamoto University Hospital, Kumamoto, Japan.
- Department of Gastroenterology and Hepatology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
- Department of Surgery, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
- Department of Pathology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Zitieren
APA
Miyata, T., Sugi, K., Horino, T., Ono, A., Tagayasu, Y., Nomoto, D., Inoue, M., Mizumoto, T., Kubota, T., Yanagida, E., Murayama, T., Miyanari, N., & Baba, H. (2023). Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture. Anticancer Research. https://doi.org/10.21873/anticanres.16239
Vancouver
Miyata T, Sugi K, Horino T, Ono A, Tagayasu Y, Nomoto D, et al. Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture. Anticancer Research. 2023. doi:10.21873/anticanres.16239
BibTeX
@article{Miyata2023,
author = {Miyata, Tatsunori and Sugi, Kazuhiro and Horino, Taichi and Ono, Asuka and Tagayasu, Yoshiyuki and Nomoto, Daichi and Inoue, Mitsuhiro and Mizumoto, Takao and Kubota, Tatsuo and Yanagida, Eriko and Murayama, Toshihiko and Miyanari, Nobutomo and Baba, Hideo},
title = {Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16239}
}
EUVIMED